GettyImages/Tatsiana Volkava
Signos Inc. announced a $20 million funding round on Wednesday, with backing from GV (Google $GOOGL -0.70% Ventures), Dexcom, and Blue Cross Blue Shield of Alabama, alongside a new distribution deal that will make the startup's subscription plans available on Dexcom's direct-to-consumer website.
Signos was founded to improve metabolic health using technology. The company created an AI-powered glucose monitoring platform for weight management and became the first in its category to receive FDA clearance in 2025. The system uses a Dexcom biosensor to track glucose levels, then analyzes data related to eating, rest, and stress to provide personalized advice for healthier habits.
As part of the expanded partnership, Signos will be sold through Stelo.com, Dexcom's direct-to-consumer site. Dexcom also participated in the funding round. "Signos has developed a system that translates glucose biosensing data into actionable insights for people focused on weight management," said Jon Coleman, Dexcom's chief commercial officer, in a statement. "Making Signos available on Stelo.com is a natural next step."
Among the planned uses for the new investment is a build-out of predictive AI capabilities, including a meal-scoring function that draws on individual user history to assess potential glucose impact before a person eats, according to CNBC.
